60 DEGREES PHARMACEUTICALS, INC. (SXTP) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.99

From 52W high−86.72%

Volume31483.00

Market cap$3.36M

P/E (TTM)—

P/S (TTM)3.0x

Div yield—

Key dataSep 18, 2026

Open

$0.99

From 52W high

−86.72%

Volume

31483.00

Market cap

$3.36M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.5x

P/E (TTM)

—

RSI (14)

45.3

MomentumView details →

1D Return

−3.69%

YTD Return

−51.26%

SummaryUpdated Jun 1, 2026

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) is a specialty pharmaceutical company founded in 2010 and headquartered in Washington, D.C. The company went public in July 2023 and focuses on developing and commercializing therapies for the prevention and treatment of infectious diseases. Since its IPO, the company has experienced significant stock price volatility, declining from over $16 per share in 2023 to around $2 per share currently, reflecting the challenges typical of early-stage biotech companies with limited commercial revenue.

Ask drillr about 60 DEGREES PHARMACEUTICALS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.5x

EV/Sales

10.8x

P/S (TTM)

3.0x

P/B (TTM)

1.3x

ProfitabilityView details →

Gross Margin

19.42%

Net Margin

−730.23%

EBITDA Margin

−725.99%

ROE (TTM)

−310.33%

ROA (TTM)

−189.43%

Asset Turnover

0.20x

GrowthView details →

Revenue YoY

+68.02%

EPS YoY

+81.53%

FCF YoY

—

Revenue CAGR 3Y

+65.15%

EPS CAGR 3Y

+84.19%

EBITDA YoY

−4.11%

MomentumView details →

1D Return

−3.69%

YTD Return

−51.26%

1Y Return

−81.81%

RSI (14)

45.3

vs 50D SMA

−16.91%

vs 200D SMA

−51.85%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

2.32x

Quick Ratio

1.78x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.90

EPS Surprise

−21.62%

Beats (12Q)

1/12

Next Q EPS Est

−$0.61

Avg Surprise (4Q)

−36.45%

Rev Surprise

13.00%

Financials snapshotView financials →

Revenue (TTM)

1.11M

Net Income (TTM)

−8.11M

Op. CF (TTM)

−8.77M

Next earningsNov 12, 2026 →

Latest newsMore news →

60 Degrees Pharmaceuticals, Inc. signed a securities purchase agreement for a private placement offering of common stock, pre-funded warrants, and Series A and Series B common warrants, with gross proceeds of approximately $1.0 million.48d ago

Similar companies

GeoVax Labs, Inc.GOVX Aptevo Therapeutics Inc.APVO XORTX Therapeutics Inc.XRTX HCW Biologics Inc.HCWB Silo Pharma, Inc.SILO Revelation Biosciences, Inc.REVB Find similar companies →

Latest newsMore news →

60 Degrees Pharmaceuticals reported its financial results for the second quarter of 2026, with net product revenues increasing approximately 106% to about $208 thousand from about $101 thousand in the same quarter of 2025.37d ago 60 Degrees Pharmaceuticals, Inc. signed a securities purchase agreement for a private placement offering of common stock, pre-funded warrants, and Series A and Series B common warrants, with gross proceeds of approximately $1.0 million.48d ago